

# Scientific Panel on Dietetic Products, Nutrition and Allergies

## Draft Agenda of the 85<sup>th</sup> Plenary meeting

**(Revision 1)**

**27-29 June 2018, Parma (Italy)**

**Auditorium:**

**Meeting open to Observers**

**OPEN SESSION**

**28-29 June 2018**

**28 June 2018, 9:00-18:00**

**29 June 2018, 9:00-13:30**

- 1. Welcome and apologies for absence - [28 June am]**
- 2. Brief introduction of Panel members and observers [28 June am]**
- 3. Adoption of the agenda**
- 4. Declarations of Interest of Scientific Panel Members**
- 5. Presentation of the Guidelines for Observers [28 June am]**
- 6. Report on written procedures since 84<sup>th</sup> Plenary meeting**
- 7. Scientific outputs submitted for possible adoption/endorsement for release for public consultation**
  - 7.1. Draft guidance on the scientific requirements for health claims related to muscle function and physical performance (Revision 1, [EFSA-Q-2018-00243](#)) - [28 June pm]
  - 7.2. Outcome of the public consultation on the draft protocol for dietary sugars ([EFSA-Q-2017-00828](#)) and Protocol for the assessment of the mandate on dietary sugars ([EFSA-Q-2017-00646](#)) - [28 June am]

- 7.3. Draft technical report on the outcome of the public consultation on the draft opinion on the update of the tolerable upper intake level for vitamin D for infants ([EFSA-Q-2018-00286](#)) [28 June pm]
- 7.4. Draft opinion on the update of the tolerable upper intake level for vitamin D for infants ([EFSA-Q-2017-00208](#)) [28 June pm]
- 8. New Mandates** [29 June am]
- 9. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission** [29 June am]
  - 9.1. Scientific Committee
  - 9.2. EFSA including its Working Groups /Task Forces
  - 9.3. European Commission
- 10. Other scientific topics for information and/or discussion -** [28 June pm - 29 June am]
  - 10.1. Draft Scientific Opinion on dietary reference values (DRVs) for sodium ([EFSA-Q-2011-01224](#))
  - 10.2. Draft Scientific Opinion on the appropriate age of introduction of complementary feeding into an infant's diet ([EFSA-Q-2016-00482](#))
  - 10.3. EFSA call for data for the safety assessment of Astaxanthin ([EFSA-Q-2018-00247](#))
- 11. Questions from and answers to Observers (in application of the guidelines for Observers)** - [29 June 11-13 am]
- 12. Any other business** - [29 June am]

**CLOSED SESSION**  
**27 June 2018, 9.00-18.00**

Items for Closed Session owing to confidential business information/proprietary data

**13. Scientific outputs submitted for possible adoption**

***Applications pursuant to Article 14/13.5 of Regulation (EC) No 1924/2006*** [27 June pm]

13.1. Han-Asiabiotech GmbH – “Symbiosal and lowering the rise of blood pressure when used as a replacement to table salt. The rising of blood pressure is a risk factor for hypertension” (Art. 14, 0467\_DE, [EFSA-Q-2018-00002](#))

13.2. Probi AB - “*Lactobacillus plantarum* 299v increases non-heme iron absorption” (Art. 13.5, 0466\_SE, [EFSA-Q-2017-00820](#))

***Novel Foods*** [27 June am]

13.3. Armor Protéines S.A.S.– Draft opinion on Whey Protein Isolate ([EFSA-Q-2018-00104](#))

13.4. Longlive Europe Food Division Ltd – Draft opinion on xylo-oligosaccharide ([EFSA-Q-2017-00665](#))

13.5. Unilever NV/Unilever PLC – Draft opinion on Allanblackia seed oil ([EFSA-Q-2018-00226](#))

13.6. Bionova LLC - The egg membrane hydrolysate ([EFSA-Q-2018-00103](#))

**14. Other scientific topics for information and/or discussion (cont.)** [27 June am]

14.1. Cranberry' extract powder as a novel food pursuant to Article 26(2)(c) of Regulation (EU) 2015/2283 – proprietary data